Desired vancomycin trough concentration to achieve an AUC0‐24/MIC ≥400 in Chinese children with complicated infectious diseases
暂无分享,去创建一个
Zhenyu Pan | Yuzhu Dong | Qian Du | Dan Sun | Yalin Dong | Tao Zhang | Ying Zhang | Xiaoliang Cheng | Hua Cheng | Jie Mi
[1] Yuzhu Dong,et al. Paediatric acute kidney injury induced by vancomycin monotherapy versus combined vancomycin and meropenem , 2019, Journal of clinical pharmacy and therapeutics.
[2] X. Liang,et al. A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] J. Lykkesfeldt,et al. Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. , 2018, Basic & clinical pharmacology & toxicology.
[4] R. Cohen,et al. Antibiotic pharmacokinetic and pharmacodynamic parameters in pediatric clinical practice. , 2017, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[5] W. Lu,et al. Population pharmacokinetics of vancomycin in Chinese pediatric patients . , 2017, International journal of clinical pharmacology and therapeutics.
[6] E. Heil,et al. Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population. , 2017, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
[7] C. Thomson,et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. , 2016, Annals of the American Thoracic Society.
[8] Peggy Cruse,et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] P. Gao,et al. Pharmacokinetic Characteristics and Clinical Outcomes of Vancomycin in Young Children With Various Degrees of Renal Function , 2016, Journal of clinical pharmacology.
[10] J. Le,et al. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[11] M. Sharland,et al. Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. , 2016, The Journal of antimicrobial chemotherapy.
[12] J. Vallejo,et al. Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome , 2016, The Pediatric infectious disease journal.
[13] J. Pachón,et al. Optimizing the Clinical Use of Vancomycin , 2016, Antimicrobial Agents and Chemotherapy.
[14] P. G. Choe,et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. , 2015, International journal of antimicrobial agents.
[15] A. Widmer,et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] A. Widmer,et al. Executive Summary: 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] K. V. Van Meurs,et al. Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates , 2014, Antimicrobial Agents and Chemotherapy.
[18] C. Knoderer,et al. Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated With Acute Kidney Injury in Children? , 2014, Journal of the Pediatric Infectious Diseases Society.
[19] Lisa Lubsch,et al. Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis , 2013, Pharmacotherapy.
[20] Roger W. Jelliffe,et al. Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? , 2013, Antimicrobial Agents and Chemotherapy.
[21] B. Guglielmo,et al. Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.
[22] E. Capparelli,et al. Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure , 2013, The Pediatric infectious disease journal.
[23] K. Neville,et al. Defining Risk Factors for Red Man Syndrome in Children and Adults , 2012, The Pediatric infectious disease journal.
[24] R. Kullar,et al. Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort , 2012, Pharmacotherapy.
[25] G. Giachetto,et al. Vancomycin pharmacokinetic–pharmacodynamic parameters to optimize dosage administration in critically ill children , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[26] L. Benet,et al. Impact of a Hospitalwide Increase in Empiric Pediatric Vancomycin Dosing on Initial Trough Concentrations , 2011, Pharmacotherapy.
[27] Thomas M. English,et al. Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients , 2011, The Annals of pharmacotherapy.
[28] R. Kullar,et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] L. Benet,et al. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. , 2010, Clinical therapeutics.
[31] D. Levine,et al. Therapeutic Monitoring of Vancomycin in Adults , 2009, Pharmacotherapy.
[32] G. Drusano,et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] PharmD Lynn L. Estes. Therapeutic Monitoring of Vancomycin in Adults , 2009 .
[34] B. Murray,et al. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] G. Eliopoulos,et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. , 2006, The Journal of antimicrobial chemotherapy.
[36] George L. Drusano,et al. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.
[37] P. Ward,et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[39] R. Wrishko,et al. Vancomycin Pharmacokinetics and Bayesian Estimation in Pediatric Patients , 2000, Therapeutic drug monitoring.
[40] J. Rotschafer,et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. , 1996, The Journal of antimicrobial chemotherapy.
[41] W. Leader,et al. Pharmacokinetic Optimisation of Vancomycin Therapy , 1995, Clinical pharmacokinetics.
[42] N. Saunders. Why monitor peak vancomycin concentrations? , 1994, The Lancet.
[43] J. Rotschafer,et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique , 1993, Antimicrobial Agents and Chemotherapy.
[44] F. Vaida,et al. Population-Based Pharmacokinetic Modeling of Vancomycin in Children with Renal Insufficiency. , 2014, Journal of pharmacology & clinical toxicology.
[45] B. Bruguerolle,et al. Vancomycin: a review of population pharmacokinetic analyses. , 2012, Clinical pharmacokinetics.
[46] D. Levine,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[47] M. Rybak,et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] W. Craig,et al. Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .
[49] P. Landais,et al. [Acute renal failure associated with drugs or iodinated contrast media. Results of a cooperative multicentric study by the Nephrology Society]. , 1986, Nephrologie.
[50] G. Mccracken,et al. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. , 1981, Reviews of infectious diseases.